ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0025

Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease

Elio Carmona1, Rabia Deniz2, Cemal Bes3, Haner Direskeneli4, Ahmet Gul5 and Amr Sawalha6, 1Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, 2University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, 3University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, 4Marmara University, ISTANBUL, Turkey, 5Istanbul University, Istanbul, Turkey, 6University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2025

Keywords: Behçet's Syndrome, genomics, Monocytes/macrophages, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0019–0048) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant role in BD, with studies indicating alterations in monocyte subsets and functions. However, the detailed transcriptional programs and subset-specific contributions of monocytes to BD pathogenesis remain to be fully characterized. In this study, we leveraged single-cell transcriptomics to uncover monocyte subset-specific immune alterations in BD.

Methods: We performed single-cell RNA sequencing using GEM-X technology (10X Genomics) on PBMCs from 50 individuals (38 BD patients, 12 matched healthy controls). Sample multiplexing was enabled by antibody-based cell hashing. Data preprocessing, normalization, and clustering were performed using Seurat v5. Differential expression, cell composition analyses, and pathway enrichment (GO and GSEA) were conducted to identify disease-associated profiles.

Results: After quality control filtering, we analyzed a total of 251,924 PBMCs, successfully characterizing all major immune cell populations. Focusing on monocyte subsets, we observed significant transcriptional alterations in BD patients. CD14⁺ monocytes exhibited a significant expansion compared to healthy controls as well as an upregulation of inflammatory and interferon-stimulated genes including IFI27, IFITM1/2, IFI6, and S100A9. Gene Ontology analysis showed enrichment of cytokine signaling and innate immune activation pathways. Gene Set Enrichment Analysis (GSEA) further highlighted hallmark pathway enrichment for inflammatory response and IL6/JAK/STAT3 signaling, consistent with known BD immunopathology. Similarly, CD16⁺ monocytes were expanded in BD but exhibited a distinct transcriptional program. Upregulated genes included cytotoxicity-associated effectors (PRF1, GIMAP4–8), chemotactic receptors (CCR5, CX3CR1, CMKLR1), inflammasome components (CASP1, PYCARD), and stress-response genes (HSPA1A, HSPA6). Increased expression of immune checkpoints (CD200R1, SLAMF6, BTLA) and ISGs (RSAD2, IFI44L, OAS1) suggested a pro-inflammatory, non-classical activation state in CD16⁺ monocytes. Functional enrichment pointed to immune effector functions, cell death, and migration pathways.

Conclusion: Our study provides a comprehensive single-cell map of PBMCs in Behçet’s disease, revealing profound transcriptional remodeling of monocyte subsets. While CD14⁺ monocytes display canonical inflammatory features, we identify an expansion of CD16⁺ monocytes with a distinct cytotoxic, chemotactic, and interferon-responsive profile. These findings highlight monocyte heterogeneity in BD and uncover candidate pathways that may guide future therapeutic strategies targeting innate immune dysregulation.


Disclosures: E. Carmona: None; R. Deniz: None; C. Bes: None; H. Direskeneli: None; A. Gul: None; A. Sawalha: None.

To cite this abstract in AMA style:

Carmona E, Deniz R, Bes C, Direskeneli H, Gul A, Sawalha A. Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/expansion-and-transcriptional-reprogramming-of-cd14%e2%81%ba-and-cd16%e2%81%ba-monocytes-in-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-and-transcriptional-reprogramming-of-cd14%e2%81%ba-and-cd16%e2%81%ba-monocytes-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology